1.3 Sample Standard of Care from the Medical University of South Carolina



Vitamin D Testing and Treatment Protocol MUSC Department of Ob-Gyn, Maternal-Fetal Medicine Division

BACKGROUND:

A rapidly evolving body of literature, including sentinel studies done by Carol Wagner and colleagues here at MUSC, has documented both the perinatal and child health benefits of achieving therapeutic 25-0H Vitamin D levels (> 40 ng/ml) during pregnancy. Simultaneously, we are aware that almost 80% of our obstetrical population and virtually 100% of our African-American obstetrical population have 25-0H Vitamin D levels that fall below this therapeutic threshold.

Studies by Wagner as well as others have demonstrated significant reductions in the rate of preterm birth among pregnant women who achieve 25-0H Vitamin D levels greater than 40 ng/ml via prenatal supplementation. Vitamin D deficiency and appropriate supplementation may both explain and help improve the high rates of premature birth in our community and region. Other potential perinatal benefits include the possibility of reducing the incidences of Gestational Diabetes, pre-eclampsia, depression and postpartum depression.

Perinatal supplementation and achievement of therapeutic maternal 25-0H Vitamin D levels has also been associated with improved neonatal and childhood immune function. This improved immune function has translated into reduced risks of upper respiratory infection, bronchitis, ear infections and pneumonia. A soon to be published prospective randomized trial will demonstrate a significant reduction in childhood asthma among the children of women who achieve therapeutic Vitamin D levels during pregnancy.

Figure 1. illustrates the potential disease incidence prevention associated with increasing the 25-0H Vitamin D level to > 40 ng/ml. The recommended range for 25-0H Vitamin D is between 40-60 ng/ml.

PROTOCOL:

- 1. A 25-OH Vitamin D level will be obtained routinely as part of the New OB prenatal blood work.
- 2. If the 25-0H Vitamin D level is < 40 ng/ml you can begin supplementation with 5000 IU of Vitamin D per day.

- 3. More specific supplementation dosing can be achieved with the use of Figure 2. which provides a recommended daily dose of 25-0H Vitamin D based on the initial starting level and anticipating a goal of > 40 ng/ml.
- 4. Using the chart in Figure 2. to get 90% of the patients from an initial level of 20 ng/ml (many are even lower) to a level of 45 ng/ml, the likely required daily dose will be 5000 IU / day.
- 5. GrassrootsHealth through the Protect Our Children NOW! Project has provided free Vitamin D (5000 IU capsules) for your patients that they can receive from our perinatal nurses at visit check out. Their receipt of this prescription will be documented in EPIC Meds and Orders.
- 6. The 25-0H Vitamin D level should be rechecked along with the routine Glucola screen at 24-28 weeks gestation. Vitamin D dosing adjustments can be made based on this mid-trimester measurement.
- 7. The 25-OH Vitamin D level should be checked a third time at 34-36 weeks gestation along with the third trimester CBC and / or STD blood work. A further dosage adjustment can be made at that time if required.
- The 25-0H Vitamin D level is covered by insurance as part of the prenatal panel. Follow up testing is also covered if "Vitamin D Deficiency" is added to the problem list if the Vitamin D level is < 40 ng/ml.

TOXICITY:

Vitamin D toxicity is an uncertain entity and rarely encountered. Most labs will identify a 25-0H Vitamin D level of > 100-120 ng/ml as being potentially toxic. Toxicity is typically defined by elevations of the serum or urinary calcium levels and potentially kidney stones. We have not encountered any Vitamin D levels that high either before or after supplementation. Nor have we encountered any side effects attributed to Vitamin D supplementation. This experience includes several high dose Vitamin D supplementation trials by Dr. Wagner. Published literature shows no toxicity under 200 ng/ml and 30,000 IU/day. This greatly exceeds any dosing regimen we would have.

It is important to perform follow up Vitamin D testing as there can be significant individual variation in the response to Vitamin D supplementation.

MANAGEMENT TIPS:

Obviously not all patients show up in the first trimester for their initial prenatal visit. Additionally, at MUSC we see a number of women referred at later gestational ages due to high risk conditions. Many of these women will have already had their prenatal blood work performed.

If these women are seen later in pregnancy, please obtain a 25-0H Vitamin D level if not already performed. Based on results, initiate aggressive supplementation as soon as possible. With daily supplementation maternal Vitamin D levels can normalize as quickly as 2 months. Vitamin

D is believed to prevent preterm birth through its anti-inflammatory and immune modulating properties. Therefore, supplementation even in just the third trimester is still beneficial. Another inevitable issue is when and how to initiate supplementation. Selecting a dose based on measured Vitamin D levels is ideal, but misses the opportunity to discuss and initiate treatment at that first prenatal visit. That missed opportunity becomes more problematic when it is remembered that 80% of all our patients and 100% of our African- American patients are Vitamin D deficient (<40 ng/ml).

What I do is inform my patients of the above reality and prescribe 5000 IU of Vitamin D3 capsules (that are currently provided free). I recommend that my patient take 1/day (5000 IU) until their Vitamin D level is available. If worse than anticipated I can use the chart and increase the frequency of intake to 8+ times/week, if better than anticipated I can decrease to <7 times/week. If the level is > 40 ng/ml, again, frequency of intake is determined by serum level.

PROJECT FOLLOW-UP:

In a collaboration between MUSC and GrassrootsHealth we will use electronic medical records and perinatal outcome summary data to assess the uptake and impact of the Vitamin D testing and supplementation program on Obstetrical outcomes at MUSC.

As a greater number of obstetrical patients are tested for Vitamin D deficiency and appropriately supplemented to achieve levels > 40 ng/ml we expect to see measurable reductions in our institution's preterm delivery rate as well as potentially other perinatal measures.

Roger Newman, MD Professor and Maas Endowed Chair of Reproductive Sciences



Title:	Vitamin D	Date Originated: 5/27/16
Clinic:	MUSC Women's Health	Annual Review Date:
Owner:	Patricia Condon, MSN, RN	Revision Date:

Purpose: Provide Vitamin D3 Supplementation to OB patients as >80% of pregnant women are Vitamin D Deficient

Policy: Provide Vitamin D3 Supplementation to OB patients at first prenatal visit.

Procedure: 25-hydroxyvitamin D serum level is drawn with OB labs Provide Vitamin D Supplementation to patient to begin, Vitamin D3 5,000 units #250 as a sample. Patient to take one daily.


Additional Information:

- 1) State any **reasons for contacting the physician** before initiating the standing orders NA
- 2) Identify any **patient/family notification and/or education** that needs to occur Vitamin D supplementation is reviewed in OB Session I with patient by RN
- 3) State **documentation process** (specifics of what to document and where to document in Epic/EMR) and procedure for forwarding information to the physician's queue in Epic for review and signature Document as a standing order in EPIC.

Signature: Service Line or Lead Medical Director:

mus

Date: 5-27.16



Legend:

All percentages reference a common reference level of 25.0 ng/ml as shown on the chart. %'s reflect the disease prevention % at the beginning and ending of available data. Example: Gestational diabetes incidence is reduced by 11% when the serum level is 30.7 ng/ml vs the reference level of 25.0 ng/ml. There is a 33% reduction in incidence when the serum level is 41.9 ng/ml vs the reference level of 25.0 ng/ml.

References

References: Preterm Birth: Wagner CL, et al. 17th Workshop on Vitamin D; 2014 June 17-20. Hypertensive Pregnancy Disorders, Gestational Diabetes, and Bacterial Vaginosis: Wag-ner CL, et al. J Steroid Biochem Mol Biol. 2013;136:313-320. Depression: Huang JY, et al. J Womens Health. 2014;23(7):588-95. Impaired Muscle Strength: Kalliokoski P, et al. BMC Pregnancy Childbirth. 2013;13(237). Postpartum Depression: Gur EB, et al. Eur J Obstet Gynecol Reprod Biol. 2014;179:110-8. Small for Gestational Age: Gernand, AD, et al. Obstet Gynecol. 2014;123(1):40-8. Common Cold, Ear Infection, and Lung Inflammation: Shin YH, et al. Korean J Pediatr. 2013;56(10):439-445. Asthma: Magnus MC, et al. Paediatr Perinat Epidemiol. 2013;27(6).

Copyright GrassrootsHealth, 02/1/15 www.grassrootshealth.net

Figure 1

Change in Serum Level Based on Intake (IU/day) for 90% of Adults* (N=7324)								
Expected Level ► (ng/ml)		20	30	40	50	60		
Current Level > (ng/ml)	10	2000	4000	6000	10,000	10,000		
	15	1000	3000	6000	9000	10,000		
	20		2000	5000	8000	10,000		
	25		1000	4000	7000	10,000		
	30			3000	6000	10,000		
	35			1000	5000	9000		
	40				3000	8000		
	45				2000	6000		
	50					4000		

* values rounded to the nearest 1000 IU; highest recommended intake is 10,000 IU/day

Example: With a starting serum level of 20 ng/ml, an additional intake of approximately 5000 IU/day would be sufficient for 90% of adults (age 18 years and older, weighing 150 lbs) to achieve a serum level of at least 40 ng/ml.



Figure 2